209
Views
0
CrossRef citations to date
0
Altmetric
ASSISTED REPRODUCTION

Discordance between day-3 follicle stimulating hormone & anti-Müllerian hormone is predictive of clinical pregnancy during fertility treatment

, , &
Pages 798-801 | Received 26 Nov 2019, Accepted 08 Dec 2020, Published online: 23 Dec 2020

References

  • American College of Obstetricians and Gynecologists. Ovarian reserve testing. Committee Opinion No. 618. Washington, DC. Obstet Gynecol 2015. 125:268–273.
  • Leader B, Hegde A, Baca Q, et al. High frequency of discordance between antimullerian hormone and follicles stimulating hormone levels in serum from estradiol-confirmed days 2 to 4 of the menstrual cycle from 5,354 women in U.S. fertility centers. Fertil Steril. 2012;98(4):1037–1042.
  • Tal R, Tal O, Seifer BJ, et al. Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis. Fertil Steril. 2015;103(1):119–130.
  • Singer T, Barad DH, Weghofer A, et al. Correlation of antimüllerian hormone and baseline follicle-stimulating hormone levels. Fertil Steril. 2009; 91(6):2616–2619.
  • Barad DH, Weghofer A, Gleicher N. Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function. Fertil Steril. 2009;91(Suppl 4):1553–1555.
  • Tremellen K, Kolo M. Serum anti-Mullerian hormone is a useful measure of quantitative ovarian reserve but does not predict the chances of live-birth pregnancy. Aust N Z J Obstet Gynaecol. 2010;50(6):568–572.
  • Bakas P, Boutas I, Creatsa M, et al. Can anti-Mullerian hormone (AMH) predict the outcome of intrauterine insemination with controlled ovarian stimulation? Gynecol Endocrinol. 2015;31(10):765–768. Gynecol Endocrinol. 2015;31(10):765‐768.
  • Moreau J, Gatimel N, Simon C, et al. Age-specific anti-Mullerian hormone (AMH) levels poorly affects cumulative live birth rate after intra-uterine insemination. Eur J Obstet Gynecol Reprod Biol X. 2019;3:100043.
  • Buyuk E, Seifer D, Younger J, et al. Random anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels. Fertil Steril. 2011; 95(7):2369–2372.
  • Smeenk JM, Sweep FC, Zielhuis GA, et al. Antimullerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. Fertil Steril. 2007;87(1):223–226.
  • Iliodromiti S, Kelsey TW, Wu O, et al. The predictive accuracy of anti-Müllerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature. Hum Reprod Update. 2014;20(4):560–570.
  • Gleicher N, Weghofer A, Barad DH. Discordances between follicle stimulating hormone (FSH) and anti-Müllerian hormone (AMH) in female infertility. Reprod Biol Endocrinol. 2010;8:64.
  • Molinaro T, Samara A. Patients with discordant AMH and FSH have a better prognosis in in-vitro fertilization than those with two abnormal markers of ovarian reserve. Fertil Steril. 2011;96(3):S199.
  • Younis A, Hawkins K, Butler W. Validation of the access AMH assay & its comparison with labcorp ultrasensitive assay. Fertil Steril. 2016; 104:S155. P-367.
  • Ligon S, Lustik M, Levy G, et al. Low antimüllerian hormone (AMH) is associated with decreased live birth after in vitro fertilization when follicle-stimulating hormone and AMH are discordant. Fertil Steril. 2019;112(1):73–81.
  • Freiesleben N, Rosendahl M, Johannsen TH, et al. Prospective investigation of serum anti-Mullerian hormone concentration in ovulatory intrauterine insemination patients: a preliminary study. Reprod Biomed Online. 2010;20(5):582–587.
  • Li HW, Yeung WS, Lau EY, et al. Evaluating the performance of serum anti-Mullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine insemination. Fertil Steril. 2010;94(6):2177–2181.
  • Fauser BCJM, Diedrich K, Devroey P, Evian Annual Reproduction Workshop Group 2007. Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum Reprod Update. 2008;14(1):1–14.
  • Toner JP, Seifer DB. Why we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimüllerian hormone. Fertil Steril. 2013; 99(7):1825–1830.
  • Riggs RM, Duran EH, Baker MW, et al. Assessment of ovarian reserve with anti-Müllerian hormone: a comparison of the predictive value of anti-Müllerian hormone, follicle-stimulating hormone, inhibin B and age. Am J Obstet Gynecol. 2008;199(2):199-202.e1–202.e8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.